| Strategy | Cost/DALY |
| ACE-inhibitor (CHF) | Cost saving |
| Aspirin/β-blocker (post MI) | Cost saving |
| ASA/BB (AMI) | 11 |
| ACEI/BB (CHF) | 218 |
| Four-drug regimen – secondary prevention | 350 |
| Streptokinase (AMI) | 634 |
| Four-drug regimen – primary prevention (10-year risk >15%) | 900 |
| Diabetes (intensive glycaemic control – HbA1c >8.0) | 1810 |
| Diabetes screening | 3870 |
| tPA (AMI) | 15 900 |
| CABG (post-MI) | 27 000 |